Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

Vertex Pharmaceuticals (Nasdaq ... Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and ...

By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq ... Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

Vertex Pharmaceuticals (VRTX ... For more information please view the Barchart Disclosure Policy here. With headquarters in the heart of Chicago's financial district, Barchart has been an industry ...

A UK market access summit convened by IQVIA brought together pharma and NHS leaders to ... attention of your UK general manager, but also global headquarters.” The growing role of NHS England ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko ...